NICE
ABPI warns of postcode prescribing
January 21, 2011Sales and Marketing ABPI, Cancer Drugs Fund, NICE, cancer drug prescribing, postcode prescribing
The ABPI has said the government’s forthcoming Cancer Drugs Fund could increase the problems of postcode prescribing. The UK industry …
Health Bill continues fast pace of NHS reform
January 20, 2011Sales and Marketing GP consortia, NHS, NHS Commissioning Board, NHS reforms, NICE, QALY
The government has outlined its draft Health and Social Care Bill, making some minor concessions to critics but promising no …
Leukaemia drug fast-tracked by NICE
January 6, 2011Sales and Marketing Bendamustine, Levact, NICE, Napp, chronic lymphocytic leukaemia, leukaemia
A treatment for patients with the most common form of leukaemia has been fast tracked by NICE because of strong …
NICE’s public health role reduced
January 4, 2011NHS, NHS reforms, NICE, public health, quality standards
NICE’s public health remit has been slimmed down as part of the government’s reforms with the removal of six areas …
GSK’s patient access scheme for Votrient sways NICE
December 24, 2010Sales and Marketing GSK, GlaxoSmithKline, NICE, Votrient, pazopanib, rcc, renal cell carcinoma
NICE has recommended GlaxoSmithKline’s kidney cancer drug Votrient in final draft guidance after the pharma company offered to implement a …
NICE no for Avastin in breast cancer
December 8, 2010Sales and Marketing NICE, Roche, avastin, bevacizumab, breast cancer, health technology assessment, hta
NICE has refused to back Roche’s Avastin for use in breast cancer patients citing the blockbuster drug’s high cost and …
NICE recommends MabThera for non-Hodgkin’s lymphoma
December 6, 2010Sales and Marketing MabThera, NICE, Rituxan, Roche, non-Hodgkin’s lymphoma, rituximab
NICE has given a preliminary green-light to Roche’s MabThera for use as a maintenance therapy for non-Hodgkin’s lymphoma. The Institute’s …
Change is needed, concedes NICE chief, but defends record
November 30, 2010Sales and Marketing Andrew Dillon, NHS reform, NICE, cost-effectiveness, health technology assessment, hta, value-based pricing
The chief executive of NICE acknowledges changes are needed in how drugs are assessed in the UK – including more …
Novartis fails to sway NICE with Afinitor deal
November 26, 2010Sales and Marketing Afinitor, Kidney cancer, NICE, Novartis, advanced renal cell carcinoma, everolimus
Novartis has failed to convince NICE that its revised patient access scheme for Afinitor would make the kidney cancer drug …
Roche set to challenge NICE Tarceva decision
November 25, 2010Sales and Marketing NICE, Roche, Roche UK, Tarceva, erlotinib, lung cancer
NICE has again rejected Roche’s lung cancer drug Tarceva in its second round of draft guidance. Tarceva (erlotinib) was being …
NICE recommends Herceptin for gastric cancer, blocks high dose Glivec
November 24, 2010Sales and Marketing Cancer, GIST, Glivec, HER2, Herceptin, NICE, gastric cancer
NICE has recommended Roche’s cancer drug Herceptin for patients with HER2 metastatic gastric cancer. NICE was initially minded not to …
Irish cost-effectiveness guidelines published
November 15, 2010Sales and Marketing Dr Mairin Ryan, Economic Evaluation of Health Technologies, HIQA, Health Information and Quality Authority, IPHA, Ireland, Irish Pharmaceutical Healthcare Association, NICE, hta
The Irish government has published new health technology assessment guidelines to help decision-makers estimate the cost-effectiveness of medical treatments. The …
Digital Pharma: Pfizer and Boehringer’s online COPD awareness
November 12, 2010Medical Communications Boehringer Ingelheim, COPD, Digital Pharma blog, Managing COPD, NICE, Pfizer, Spiriva, chronic obstructive pulmonary disease
Pfizer and Boehringer Ingelheim have launched an online campaign to publicise the latest NICE guidelines on COPD to healthcare professionals …
NICE stands firm on Avastin rejection
November 12, 2010Sales and Marketing NICE, Roche, avastin, bevacizumab, colon cancer, metastatic colorectal cancer, patient access scheme
NICE has refused to recommend Roche’s blockbuster cancer drug Avastin for the treatment of metastatic colorectal cancer in its final …
NICE limits access to cancer drugs, study confirms
November 10, 2010Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, IPSOR, Maximilian Lebmeier, NICE, hta
NICE became more restrictive in its assessment of new cancer drugs between 2007 and 2009, a new report suggests. The …
